Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Famotidine + OKN4395 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Famotidine | Amfamox | |||
| OKN4395 | OKN-4395|OKN 4395 | Limited information is currently available on OKN4395, a putative EP2 and EP4 inhibitor (Jan 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06789172 | Phase I | OKN4395 + Pembrolizumab OKN4395 Famotidine + OKN4395 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (INVOKE) | Recruiting | USA | GBR | AUS | 0 |